These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 29358293)

  • 1. Amikacin Pharmacokinetic-Pharmacodynamic Analysis in Pediatric Cancer Patients.
    Alhadab AA; Ahmed MA; Brundage RC
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29358293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating amikacin dosage regimens in intensive care unit patients: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation.
    Zazo H; Martín-Suárez A; Lanao JM
    Int J Antimicrob Agents; 2013 Aug; 42(2):155-60. PubMed ID: 23756322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing Amikacin Dosage in Pediatrics Based on Population Pharmacokinetic/Pharmacodynamic Modeling.
    Alqahtani S; Abouelkheir M; Alsultan A; Elsharawy Y; Alkoraishi A; Osman R; Mansy W
    Paediatr Drugs; 2018 Jun; 20(3):265-272. PubMed ID: 29569124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of in vitro critical inhibitory concentration, a novel approach to predict in vivo synergistic bactericidal effect of combined amikacin and piperacillin against Pseudomonas aeruginosa in a systemic rat infection model.
    Chan E; Zhou S; Srikumar S; Duan W
    Pharm Res; 2006 Apr; 23(4):729-41. PubMed ID: 16554956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Amikacin Pharmacokinetics and Pharmacodynamics for Optimal Initial Dosing Regimen.
    Kato H; Hagihara M; Hirai J; Sakanashi D; Suematsu H; Nishiyama N; Koizumi Y; Yamagishi Y; Matsuura K; Mikamo H
    Drugs R D; 2017 Mar; 17(1):177-187. PubMed ID: 28063020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamics of inhaled amikacin (BAY 41-6551) studied in an in vitro pharmacokinetic model of infection.
    Bowker KE; Noel AR; Tomaselli S; Attwood M; MacGowan AP
    J Antimicrob Chemother; 2018 May; 73(5):1305-1313. PubMed ID: 29562340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of Synergistic Combination Regimens against Carbapenem- and Aminoglycoside-Resistant Clinical Pseudomonas aeruginosa Isolates via Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling.
    Yadav R; Bulitta JB; Nation RL; Landersdorfer CB
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27821448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the pharmacokinetics and pharmacodynamics of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infections using data from two phase 2 clinical studies.
    Okusanya OO; Bhavnani SM; Hammel JP; Forrest A; Bulik CC; Ambrose PG; Gupta R
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5005-15. PubMed ID: 24687506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amikacin target achievement in adult cystic fibrosis patients utilizing Monte Carlo simulation.
    Nolt VD; Pijut KD; Autry EB; Williams WC; Burgess DS; Burgess DR; Arora V; Kuhn RJ
    Pediatr Pulmonol; 2019 Jan; 54(1):33-39. PubMed ID: 30507069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic Evaluation of Plasma and Epithelial Lining Fluid Exposures of Amikacin against Pseudomonas aeruginosa in a Dynamic
    Heffernan AJ; Sime FB; Sarovich DS; Neely M; Guerra-Valero Y; Naicker S; Cottrell K; Harris P; Andrews KT; Ellwood D; Wallis SC; Lipman J; Grimwood K; Roberts JA
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32660986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization.
    Nielsen EI; Cars O; Friberg LE
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4619-30. PubMed ID: 21807983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetic/pharmacodynamic evaluations of amikacin dosing in critically ill patients undergoing continuous venovenous hemodiafiltration.
    Li S; Zhu S; Xie F
    J Pharm Pharmacol; 2023 Apr; 75(4):515-522. PubMed ID: 36847263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amikacin Pharmacokinetics/Pharmacodynamics in a Novel Hollow-Fiber Mycobacterium abscessus Disease Model.
    Ferro BE; Srivastava S; Deshpande D; Sherman CM; Pasipanodya JG; van Soolingen D; Mouton JW; van Ingen J; Gumbo T
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1242-8. PubMed ID: 26643339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of three dosage regimens of amikacin using pharmacokinetic models in patients with cystic fibrosis].
    Halacová M; Průsa R; Kotaska K; Vávrová V
    Cas Lek Cesk; 2004; 143(3):187-90. PubMed ID: 15134039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elucidation of the pharmacokinetic/pharmacodynamic determinants of fosfomycin activity against Pseudomonas aeruginosa using a dynamic in vitro model.
    Bilal H; Peleg AY; McIntosh MP; Styles IK; Hirsch EB; Landersdorfer CB; Bergen PJ
    J Antimicrob Chemother; 2018 Jun; 73(6):1570-1578. PubMed ID: 29506207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population Pharmacokinetic Study of the Suitability of Standard Dosing Regimens of Amikacin in Critically Ill Patients with Open-Abdomen and Negative-Pressure Wound Therapy.
    Carrié C; Delzor F; Roure S; Dubuisson V; Petit L; Molimard M; Breilh D; Biais M
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31964795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pharmacokinetic/pharmacodynamic model developed for the effect of colistin on Pseudomonas aeruginosa in vitro with evaluation of population pharmacokinetic variability on simulated bacterial killing.
    Mohamed AF; Cars O; Friberg LE
    J Antimicrob Chemother; 2014 May; 69(5):1350-61. PubMed ID: 24474432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetic and pharmacodynamic modeling of high-dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients.
    Zobell JT; Stockmann C; Young DC; Cash J; McDowell BJ; Korgenski K; Sherwin CM; Spigarelli M; Chatfield BA; Ampofo K
    Clin Ther; 2011 Nov; 33(11):1844-50. PubMed ID: 22018680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints.
    Bhavnani SM; Trang M; Griffith DC; Lomovskaya O; Hammel JP; Loutit JS; Cammarata SK; Dudley MN; Ambrose PG; Rubino CM
    Antimicrob Agents Chemother; 2022 Dec; 66(12):e0213021. PubMed ID: 36374023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amikacin Initial Dose in Critically Ill Patients: a Nonparametric Approach To Optimize
    Boidin C; Bourguignon L; Cohen S; Roger C; Lefrant JY; Roberts JA; Allaouchiche B; Lepape A; Friggeri A; Goutelle S
    Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31481443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.